CT scans better than X-rays when detecting abnormalities in patients with H1N1 virus

Oct 21, 2009

Computed tomography (CT) scans are better than standard radiography (X-rays) in showing the extent of disease in patients with the H1N1 virus, according to a study to be published online Oct. 21, 2009, in the American Journal of Roentgenology. The study will be published in the December issue of the AJR.

The study group consisted of seven patients with the . All seven patients received chest X-rays and three patients had CT scans. "All patients with CT abnormalities showed abnormal findings on the corresponding chest X-rays," said Amr M. Ajlan, M.D., lead author of the study. "However, the extent of involvement was more diffuse and the distribution of disease was better characterized on CT," said Dr. Ajlan.

"The strength of our study is that all CT scans performed showed a similar distribution of abnormalities, which might help physicians prospectively diagnose H1N1 using medical imaging," he said.

"Most cases of H1N1 are mild and self-limited; however, high-risk patients are more likely to have severe complications. Our study suggests that CT is superior to standard chest X-rays and should be the imaging modality of choice in high-risk patients," said Dr. Ajlan.

More information: This study will be posted online at www.ajronline.org , Wednesday, Oct. 21, 2009, and will appear in the December issue of the .

Source: American Roentgen Ray Society

Explore further: New drug sales help boost Novartis Q1 profit (Update)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Amgen misses 1Q views as higher costs cut profit

Apr 22, 2014

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...

Valeant, Ackman make $45.6B Allergan bid

Apr 22, 2014

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

User comments : 0

More news stories